Abstract
A growing number of studies have focused on investigating microRNAs as crucial regulators in the progression of multiple cancer types. Nevertheless, the biological effects and immunological role of miR-125b-5p in non-small cell lung cancer (lung adenocarcinoma, LUAD) have not been determined. The present study aimed to examine the function of miR-125b-5p on cell proliferation and the outcomes of LUAD patients. We utilized diverse public databases in the analysis of the expression, prognosis, diagnostic value, and immune role of miR-125b-5p in non-small cell lung cancer. The growth curve, colony formation, flow cytometry, and Transwell and invasion assays were utilized to determine the function of miR-125b-5p in LUAD progression. In this study, we found that miR-125b-5p was decreased in LUAD and correlated with poor prognosis. Pathway analyses revealed that miR-125b-5p was mainly involved in cell proliferation and immune regulation. Moreover, in vitro experiments indicated that the overexpression of miR-125b-5p significantly inhibited cell proliferation, migration, and invasion and induced cell apoptosis of LUAD. Finally, we discovered that miR-125b-5p correlated with immune cell infiltration. In summary, these results demonstrated that miR-125b-5p serves as a prognostic marker and a therapeutic target for LUAD.
Highlights
Lung cancer remains the most common deadly disease, with an estimated 2.09 million new cases and 1.76 million deaths each year (Rivera and Wakelee, 2016)
The results showed that the expression of miR-125b-5p was significantly lower in breast invasive carcinoma, bladder urothelial carcinoma, cholangiocarcinoma, colon adenocarcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma
The results demonstrated that a low expression of miR-125b-5p was correlated with poor prognosis in cervical squamous cell carcinoma and endocervical adenocarcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, ovarian serous cystadenocarcinoma, prostate adenocarcinoma, and thyroid carcinoma
Summary
Lung cancer remains the most common deadly disease, with an estimated 2.09 million new cases and 1.76 million deaths each year (Rivera and Wakelee, 2016). Non-small cell lung cancers (NSCLCs), the most common lung cancers, are known to have diverse pathological features. As the most common histologic subtype of lung cancer, lung adenocarcinoma (LUAD) usually results in a lower 5-year survival rate in lung cancer (Schwartz and Cote, 2016; Liang et al, 2021). There are many diverse treatments, including chemoradiotherapy, targeted therapy, and immunotherapy, the prognosis of LUAD remains poor because it lacks effective diagnostic markers. It is urgent to further uncover specific prognostic prediction methods for the diagnosis and treatment of lung cancer. MicroRNAs (miRNAs) are non-coding RNAs that often inhibit gene expression at the posttranscriptional level.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
